

Amanda Cano

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2187491/publications.pdf>

Version: 2024-02-01

52
papers

2,488
citations

331670

21
h-index

206112

48
g-index

53
all docs

53
docs citations

53
times ranked

2977
citing authors

#	ARTICLE	IF	CITATIONS
1	Metal-Based Nanoparticles as Antimicrobial Agents: An Overview. <i>Nanomaterials</i> , 2020, 10, 292.	4.1	769
2	Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APP ^{swe} /PS1 ^{dE9} Alzheimer's disease mice model. <i>Journal of Controlled Release</i> , 2019, 301, 62-75.	9.9	207
3	Memantine loaded PLGA PEGylated nanoparticles for Alzheimer's disease: in vitro and in vivo characterization. <i>Journal of Nanobiotechnology</i> , 2018, 16, 32.	9.1	163
4	Current Applications of Nanoemulsions in Cancer Therapeutics. <i>Nanomaterials</i> , 2019, 9, 821.	4.1	147
5	Advanced Formulation Approaches for Ocular Drug Delivery: State-Of-The-Art and Recent Patents. <i>Pharmaceutics</i> , 2019, 11, 460.	4.5	115
6	Microemulsions and Nanoemulsions in Skin Drug Delivery. <i>Bioengineering</i> , 2022, 9, 158.	3.5	72
7	Current advances in the development of novel polymeric nanoparticles for the treatment of neurodegenerative diseases. <i>Nanomedicine</i> , 2020, 15, 1239-1261.	3.3	68
8	Epigallocatechin-3-gallate loaded PEGylated-PLGA nanoparticles: A new anti-seizure strategy for temporal lobe epilepsy. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 1073-1085.	3.3	60
9	Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer's disease: from current to future challenges. <i>Journal of Nanobiotechnology</i> , 2021, 19, 122.	9.1	60
10	ADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker. <i>Biomedicine and Pharmacotherapy</i> , 2019, 113, 108661.	5.6	52
11	Epigallocatechin-3-Gallate (EGCG) Improves Cognitive Deficits Aggravated by an Obesogenic Diet Through Modulation of Unfolded Protein Response in APP ^{swe} /PS1 ^{dE9} Mice. <i>Molecular Neurobiology</i> , 2020, 57, 1814-1827.	4.0	51
12	Physicochemical and biopharmaceutical aspects influencing skin permeation and role of SLN and NLC for skin drug delivery. <i>Heliyon</i> , 2022, 8, e08938.	3.2	48
13	Dexibuprofen Biodegradable Nanoparticles: One Step Closer towards a Better Ocular Interaction Study. <i>Nanomaterials</i> , 2020, 10, 720.	4.1	44
14	The Involvement of Peripheral and Brain Insulin Resistance in Late Onset Alzheimer's Dementia. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 236.	3.4	40
15	Psoriasis: From Pathogenesis to Pharmacological and Nano-Technological-Based Therapeutics. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4983.	4.1	40
16	State-of-the-art polymeric nanoparticles as promising therapeutic tools against human bacterial infections. <i>Journal of Nanobiotechnology</i> , 2020, 18, 156.	9.1	38
17	Benzodiazepines and Related Drugs as a Risk Factor in Alzheimer's Disease Dementia. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 344.	3.4	35
18	Elastic and Ultradeformable Liposomes for Transdermal Delivery of Active Pharmaceutical Ingredients (APIs). <i>International Journal of Molecular Sciences</i> , 2021, 22, 9743.	4.1	30

#	ARTICLE	IF	CITATIONS
19	Development of Lactoferrin-Loaded Liposomes for the Management of Dry Eye Disease and Ocular Inflammation. <i>Pharmaceutics</i> , 2021, 13, 1698.	4.5	28
20	Lipid Nanoparticles for the Posterior Eye Segment. <i>Pharmaceutics</i> , 2022, 14, 90.	4.5	28
21	Epilepsy in Neurodegenerative Diseases: Related Drugs and Molecular Pathways. <i>Pharmaceutics</i> , 2021, 14, 1057.	3.8	27
22	Surface Functionalization of PLGA Nanoparticles to Increase Transport across the BBB for Alzheimer's Disease. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 4305.	2.5	26
23	Encapsulation of Active Pharmaceutical Ingredients in Lipid Micro/Nanoparticles for Oral Administration by Spray-Cooling. <i>Pharmaceutics</i> , 2021, 13, 1186.	4.5	23
24	Development of topical eye-drops of lactoferrin-loaded biodegradable nanoparticles for the treatment of anterior segment inflammatory processes. <i>International Journal of Pharmaceutics</i> , 2021, 609, 121188.	5.2	20
25	A metabolic perspective of late onset Alzheimer's disease. <i>Pharmacological Research</i> , 2019, 145, 104255.	7.1	19
26	Metformin a Potential Pharmacological Strategy in Late Onset Alzheimer's Disease Treatment. <i>Pharmaceutics</i> , 2021, 14, 890.	3.8	19
27	Role of c-Jun N-Terminal Kinases (JNKs) in Epilepsy and Metabolic Cognitive Impairment. <i>International Journal of Molecular Sciences</i> , 2020, 21, 255.	4.1	18
28	Epigallocatechin-3-gallate PEGylated poly(lactic-co-glycolic) acid nanoparticles mitigate striatal pathology and motor deficits in 3-nitropropionic acid intoxicated mice. <i>Nanomedicine</i> , 2021, 16, 19-35.	3.3	18
29	Recent Advances on Antitumor Agents-loaded Polymeric and Lipid-based Nanocarriers for the Treatment of Brain Cancer. <i>Current Pharmaceutical Design</i> , 2020, 26, 1316-1330.	1.9	17
30	Matrix metalloproteinase 10 is linked to the risk of progression to dementia of the Alzheimer's type. <i>Brain</i> , 2022, 145, 2507-2517.	7.6	16
31	Lipid Nanomaterials for Targeted Delivery of Dermocosmetic Ingredients: Advances in Photoprotection and Skin Anti-Aging. <i>Nanomaterials</i> , 2022, 12, 377.	4.1	15
32	Development and optimization of Riluzole-loaded biodegradable nanoparticles incorporated in a mucoadhesive in situ gel for the posterior eye segment. <i>International Journal of Pharmaceutics</i> , 2022, 612, 121379.	5.2	15
33	Development of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation. <i>Pharmaceutics</i> , 2022, 14, 285.	4.5	15
34	Biodegradable nanoparticles for the treatment of epilepsy: From current advances to future challenges. <i>Epilepsia Open</i> , 2022, 7, .	2.4	14
35	Pharmacological Strategies to Improve Dendritic Spines in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 82, S91-S107.	2.6	13
36	Lipid-Polymeric Films: Composition, Production and Applications in Wound Healing and Skin Repair. <i>Pharmaceutics</i> , 2021, 13, 1199.	4.5	13

#	ARTICLE	IF	CITATIONS
37	Establishing In-House Cutoffs of CSF Alzheimer's Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6891.	4.1	13
38	State of the Art on Toxicological Mechanisms of Metal and Metal Oxide Nanoparticles and Strategies to Reduce Toxicological Risks. <i>Toxics</i> , 2021, 9, 195.	3.7	11
39	The Ethyl Acetate Extract of Leaves of <i>Ugni molinae</i> Turcz. Improves Neuropathological Hallmarks of Alzheimer's Disease in Female APP ^{swe} /PS1 ^{dE9} Mice Fed with a High Fat Diet. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1175-1191.	2.6	10
40	Comparison of migration disturbance potency of epigallocatechin gallate (EGCG) synthetic analogs and EGCG PEGylated PLGA nanoparticles in rat neurospheres. <i>Food and Chemical Toxicology</i> , 2019, 123, 195-204.	3.6	10
41	Antimycotic nail polish based on humic acid-coated silver nanoparticles for onychomycosis. <i>Journal of Chemical Technology and Biotechnology</i> , 2021, 96, 2208-2218.	3.2	9
42	Photoprotection and skin irritation effect of hydrogels containing hydroalcoholic extract of red propolis: A natural pathway against skin cancer. <i>Heliyon</i> , 2022, 8, e08893.	3.2	9
43	Lipid Nanocarriers for Hyperproliferative Skin Diseases. <i>Cancers</i> , 2021, 13, 5619.	3.7	8
44	Automatized FACEmemory [®] scoring is related to Alzheimer's disease phenotype and biomarkers in early-onset mild cognitive impairment: the BIOFACE cohort. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 43.	6.2	8
45	Dexibuprofen ameliorates peripheral and central risk factors associated with Alzheimer's disease in metabolically stressed APP ^{swe} /PS1 ^{dE9} mice. <i>Cell and Bioscience</i> , 2021, 11, 141.	4.8	7
46	BIOFACE: A Prospective Study of Risk Factors, Cognition, and Biomarkers in a Cohort of Individuals with Early-Onset Mild Cognitive Impairment. Study Rationale and Research Protocols. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1233-1249.	2.6	7
47	The preclinical discovery and development of opicapone for the treatment of Parkinson's disease. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 993-1003.	5.0	5
48	Lipid-Drug Conjugates and Nanoparticles for the Cutaneous Delivery of Cannabidiol. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6165.	4.1	3
49	Epidemiology of COVID-19 in the State of Sergipe/Brazil and Its Relationship with Social Indicators. <i>Epidemiologia</i> , 2021, 2, 262-270.	2.2	1
50	Liposomal formulations of oxybutynin and resiniferatoxin for the treatment of urinary diseases: improvement of drug tolerance upon intravesical. <i>Drug Delivery and Translational Research</i> , 2021, , 1.	5.8	1
51	Combined Therapy of Chitosan and Exercise Improves the Lipid Profile, Adipose Tissue and Hepatic Alterations in an In Vivo Model of Induced-Hyperlipidemia. <i>Nutraceuticals</i> , 2022, 2, 116-131.	1.7	1
52	Dexibuprofen loaded PEGylated nanospheres for Alzheimer's disease treatment. <i>Journal of Controlled Release</i> , 2017, 259, e29-e30.	9.9	0